Giovani di GesùTechnology Apple’s Reach Reshapes Medical ResearchThe New York Times - Natasha SingerIn 1976, the Harvard School of Public Health and two other major medical institutions started a study on nurses that has become one of the largest and longest research efforts ever conducted on women’s
Envision Management ConsultantsBusiness Cholesterol drug Lipitor is still generating billions for PfizerAxios - Bob Herman Lipitor, the cholesterol-lowering medication that has become the gold standard of statins, continues to generate roughly $2 billion per year in sales …
Envision Management Consultants Here's Why Teva Pharmaceuticals Dropped 13% in AugustThe Motley Fool - Maxx Chatsko Investors continued to back away from the troubled generic-drug company as lawsuits from the opioid crisis began to conclude. Shares of Teva …
Envision Management Consultants Who is next in big pharma's merger spree?Reuters - Reuters Editorial(Reuters) - Consolidation in the U.S. healthcare industry, which has already witnessed a string of multi-billion dollar deals, is expected to remain a major theme for the rest of 2019. FILE PHOTO: A sign
Envision Management ConsultantsBusiness At $2.1 Million, New Gene Therapy Is The Most Expensive Drug EverNPR - Rob SteinThe federal Food and Drug Administration has approved a gene therapy for a rare childhood disorder that is now the most expensive drug on the market. It costs $2.125 million per patient. But for those
Envision Management Consultants Novartis has 25 blockbusters in the pipeline: CEOReutersZURICH (Reuters) - Novartis has 25 potential blockbuster treatments in development, the company said ahead of a management event in the United States on Thursday. "Our pipeline is industry-leading with
Giovani di GesùBusiness Merck to Buy Cancer Drug Maker Peloton TherapeuticsThe Wall Street Journal. - Kimberly ChinAcquisition adds to list of deals by pharmaceutical companies looking to bolster their cancer treatment portfolios Merck & Co. agreed to acquire cancer drug developer Peloton Therapeutics Inc. for $1.05
Giovani di GesùMallinckrodt Mallinckrodt Stock Falls Sharply After a Warning Over Regulatory DisputeThe Wall Street Journal. - Micah MaidenbergDrug maker says a Medicare and Medicaid agency’s Acthar decision might cost firm $600 million Mallinckrodt PLC lost almost one-quarter of its stock-market value Tuesday after the drugmaker said a dispute
Envision Management Consultants Merck buys developer of oral oncology drugs valued at $2.25 billionAxios - Dan Primack Merck (NYSE: MRK) agreed to buy Peloton Therapeutics, a Dallas-based developer of oral oncology drugs. The deal is valued at upwards of $2.25 …
Envision Management Consultants Abbott Has Cash to Burn But Sees Nothing Attractive, CEO SaysBloomberg - Michelle Cortez Abbott Laboratories is back in the driver’s seat when it comes to acquisitions, Chief Executive Officer Miles White said. Problem is, nothing looks …
Envision Management Consultants U.S. senators tell drug company executives pricing is 'morally repugnant'Reuters - By Yasmeen Abutaleb and Michael ErmanWASHINGTON/NEW YORK (Reuters) - U.S. senators called drug pricing practices "morally repugnant" and told drug company executives they do not want to hear them blame others for the high prices, taking aggressive
Envision Management Consultants Johnson & Johnson Will Be The First Drug Company To Put Prescription Medication Prices in TV AdsFortune Johnson & Johnson is about to become the first big pharmaceutical company to include prescription drug prices in its medication commercials.
Envision Management Consultants Senator Sanders asks why drug, once free, now costs $375kReuters - By Yasmeen AbutalebWASHINGTON (Reuters) - U.S. Senator Bernie Sanders sent a letter to Catalyst Pharmaceuticals (CPRX.O) on Monday asking it to justify its decision to charge $375,000 annually for a medication that for has
Envision Management Consultants Amazon is everywhere, and companies can't stop mentioning itQuartz - Alison GriswoldThe modern company can work with Amazon, or work against it. Ignoring Amazon.com Inc. is no longer a viable option. The company—if company is even an adequate word to describe it—touches e-commerce, logistics,
Envision Management Consultants Another high blood pressure/heart medicine recalled for possible cancer-causing elementcharlotteobserver.com - By David J. Neal Another high blood pressure/heart medicine recalled for possible cancer-causing element A third kind of medication treating high blood pressure and/or …
Envision Management Consultants F.D.A. Panel Splits on Whether to Approve New Diabetes DrugThe New York Times - By KATIE THOMASAn advisory panel for the Food and Drug Administration split evenly on Thursday over whether the agency should approve the first oral medication to treat Type 1 diabetes. The committee voted 8-8, leaving
Envision Management ConsultantsInvesting Eli Lilly: An UpdateSeeking Alpha - DoctoRx Last October 8, I wrote my first article focusing on Eli Lilly (LLY), Eli Lilly Surges On Pipeline News: Analysis And Trading Thoughts. My analysis …
Envision Management Consultants Novartis CEO Who Wanted To Bring Tech Into Pharma Now Explains Why It's So HardForbes - David ShaywitzThe current challenge for data science and technology (DST) in healthcare is moving beyond the “dancing bear” stage, where “the wonder is not how well the bear dances, but that he dances at all.” It’s
Envision Management Consultants 2 of the world's 3 major insulin makers have hiked their U.S. prices by at least 4%Axios - Bob Herman Sanofi and Novo Nordisk, 2 of the 3 major insulin makers that dominate the global market, have raised the prices of their medications in the U.S. by …
Envision Management Consultants J&J raises U.S. prices on around two dozen drugsReuters - By Michael ErmanNEW YORK (Reuters) - Johnson & Johnson raised U.S. prices on around two dozen prescription drugs on Thursday, including the psoriasis treatment Stelara, prostate cancer drug Zytiga and blood thinner Xarelto,
Envision Management Consultants Glaxo CEO Sees 'Tremendous' Growth Opportunity After Tesaro DealBloomberg Emma Walmsley, chief executive officer at GlaxoSmithKline Plc, discusses the company's acquisition of Tesaro and its growth strategy with Bloomberg's …
Envision Management Consultants GlaxoSmithKline CEO Walmsley Says Tesaro Drug Can Give Ovarian Cancer Victims More TimeBloomberg GlaxoSmithKline Plc Chief Executive Officer Emma Walmsley discusses the deal to buy drugmaker Tesaro for $5.1 billion. She spoke to Bloomberg's …
Envision Management ConsultantsCelgene Bristol-Myers Squibb to Acquire Celgene for About $74 BillionThe Wall Street Journal. - Jared S. HopkinsThe combined company will have nine products with more than $1 billion each in annual sales Bristol-Myers Squibb Co. agreed to buy rival Celgene Corp. in a deal valued at about $74 billion, combining leading
Envision Management Consultants Novartis appoints Susanne Schaffert to lead oncology businessReuters - Reuters EditorialFILE PHOTO: A Novartis logo is pictured on its headquarters building in Mumbai April 1, 2013. REUTERS/Vivek Prakash ZURICH (Reuters) - Novartis (NOVN.S) said it appointed company veteran Susanne Schaffert
Envision Management Consultants Another Popular Blood Pressure Drug Has Been Recalled by the FDA Over Potential Cancer RiskFortune The irbesartan recall comes months the FDA's recall of valsartan, also due to potential cancer-causing contamination.
Envision Management Consultants Merck Pulls Out Of Agreement To Supply Life-Saving Vaccine To Millions Of KidsNPR - Michaeleen DoucleffThe pharmaceutical giant Merck & Co. Inc. is ending a long-term agreement to supply a lifesaving vaccine for children in West Africa. At the same time, the company has started sending the vaccine to China,
Envision Management Consultants Nonprofit drugmaker Civica Rx aims to cure a health care system ailmenttheconversation.com - Stacie B. Dusetzina Several years ago, drug shortages became headline news when supplies of three different drugs used to treat childhood cancers were running low in …
Envision Management Consultants Pfizer, Bain Form Startup Focusing on Central Nervous DisordersBloomberg - Blake Dodge Pfizer Inc. and Bain Capital LP are launching a neuroscience startup with $350 million in funding to focus on finding treatments for Alzheimer’s, …
Giovani di Gesù Indian panel wants Johnson Johnson to pay compensation over...Reuters - Aditya KalraNEW DELHI (Reuters) - A government panel has recommended that Johnson & Johnson (J&J) pay compensation of at least $28,500 to each Indian patient who suffered from artificial hip implants the U.S. healthcare
